Abstract
Inflammation is known to be involved in the progression of diabetic retinopathy. We have recently reported that vitreous levels of IL-4, IL-17A, IL-22, IL-31, and TNFα are higher than the respective serum levels in proliferative diabetic retinopathy (PDR) patients, and that vitreous levels of these cytokines are higher in PDR than in other non-inflammatory vitreoretinal diseases or uveitis associated with sarcoidosis. In the present study, we investigated inflammatory cytokines including Th17 cell-related cytokines in aqueous humor samples obtained from eyes with PDR, and analyzed the association between the aqueous humor and vitreous fluid levels of individual cytokines. The study group consisted of 31 consecutive type 2 diabetic patients with PDR who underwent cataract surgery and vitrectomy for vitreous hemorrhage and/or tractional retinal detachment. Undiluted aqueous humor was collected during cataract surgery, and then vitreous fluid was obtained using a 25G vitreous cutter inserted into the mid-vitreous cavity at the beginning of vitrectomy. IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, soluble CD40 ligand (sCD40L), and TNFα levels in the aqueous humor and vitreous fluid were measured using a beads-array system. Although IL-17A was detected in the aqueous humor of eyes with PDR and the level correlated with IL-17A level in the vitreous fluid, both percent detectable and level of IL-17A in the aqueous humor were significantly lower than those in the vitreous fluid. Vitreous IL-17A level was related significantly to IL-10, IL-22, and TNFα levels in aqueous humor as well as in vitreous fluid, On the other hand, aqueous IL-17A level was not related significantly to aqueous or vitreous levels of IL-10, IL-22 or TNFα level. The present study demonstrated that IL-17A level and detectable rate in the aqueous humor of patients with PDR are markedly lower than those in the vitreous fluid and aqueous IL-17A does not correlate with vitreous levels of other cytokines, and hence should not be used as a surrogate for IL-17A in the vitreous fluid.
Highlights
Diabetic retinopathy (DR) leading to blindness is one of the most severe complications of diabetes
We recently reported that vitreous levels of IL-4, IL-17A, IL-22, IL-31, and TNFα in proliferative DR (PDR) patients were higher than the respective levels in serum, and that vitreous levels of these cytokines were higher in PDR than in idiopathic epiretinal membrane (ERM), macular hole (MH), or uveitis associated with sarcoidosis [18]
IL-10, IL-17A, IL-22, and TNFα were detected at significantly lower percentage in the aqueous humor than in the vitreous fluid, while IL-17F, IL-25, IL-31, IFN-γ, and soluble CD40 ligand (sCD40L) were detected at significantly higher percentage, and IL-6 was detected in 100% of both aqueous humor and vitreous fluid samples
Summary
Diabetic retinopathy (DR) leading to blindness is one of the most severe complications of diabetes. In a Japanese study, the incidence of DR in type 2 diabetic patients who had no DR at baseline was 26.6% over 8 years, and the risk of progression to proliferative DR (PDR) in those with mild non-proliferative DR was 15.9% [2]. Neovascularization followed by fibrovascular changes are characteristics of PDR, and result in vitreous hemorrhage or tractional retinal detachment [5]. Various angiogenic factors such as growth factors and inflammatory cytokines have been identified in eyes with PDR, and are implicated in the progression of DR [5,6,7,8,9,10,11]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.